Q BioMed Inc. (QBIO)
| Market Cap | 24.38M |
| Revenue (ttm) | 60,000 |
| Net Income (ttm) | -10.61M |
| Shares Out | 27.59M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | 109.89 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $0.8725 |
| Previous Close | $0.8590 |
| Change ($) | 0.0135 |
| Change (%) | 1.57% |
| Day's Open | 0.8500 |
| Day's Range | 0.8500 - 0.8950 |
| Day's Volume | 39,595 |
| 52-Week Range | 0.7700 - 1.9500 |
NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, a ...
Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company, ...
Q BioMed Inc (OTCQB:QBIO) has hired WSI PBG LLC, which specializes in creating access for and selling pharmaceuticals, medical diagnostics, and durable medical equipment in the Veterans Administration, ...
NEW YORK, May 20, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creat...
Q BioMed announces up to $30M investment from insider, allowing it to advance company's growth plans
Q BioMed Inc (OTCQB:QBIO) has unveiled its largest single investment so far, with Aedesius Holdings Ltd (AedesiusOne), a privately held global disruption aggregator, investing up to $30 million in the c...
NEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a priva...
Q BioMed Inc (OTCQB:QBIO) has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus (COVID-19...
NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Researc...
Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Stron...
Q BioMed Inc (OTCQB:QBIO) has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiar...
NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injecti...
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Orga...
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designatio...
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we joi...
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member ...
About QBIO
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; ... [Read more...]
| Industry Biotechnology | Founded 2013 |
| Stock Exchange OTCMKTS | Ticker Symbol QBIO |